Mineralys Therapeutics (MLYS) Competitors $13.92 +0.52 (+3.88%) Closing price 04/14/2025 04:00 PM EasternExtended Trading$14.35 +0.43 (+3.09%) As of 08:23 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MLYS vs. RARE, AKRO, MOR, SWTX, PTGX, CPRX, MRUS, ALVO, APLS, and SRRKShould you be buying Mineralys Therapeutics stock or one of its competitors? The main competitors of Mineralys Therapeutics include Ultragenyx Pharmaceutical (RARE), Akero Therapeutics (AKRO), MorphoSys (MOR), SpringWorks Therapeutics (SWTX), Protagonist Therapeutics (PTGX), Catalyst Pharmaceuticals (CPRX), Merus (MRUS), Alvotech (ALVO), Apellis Pharmaceuticals (APLS), and Scholar Rock (SRRK). These companies are all part of the "pharmaceutical products" industry. Mineralys Therapeutics vs. Ultragenyx Pharmaceutical Akero Therapeutics MorphoSys SpringWorks Therapeutics Protagonist Therapeutics Catalyst Pharmaceuticals Merus Alvotech Apellis Pharmaceuticals Scholar Rock Ultragenyx Pharmaceutical (NASDAQ:RARE) and Mineralys Therapeutics (NASDAQ:MLYS) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability. Does the media refer more to RARE or MLYS? In the previous week, Ultragenyx Pharmaceutical had 2 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 10 mentions for Ultragenyx Pharmaceutical and 8 mentions for Mineralys Therapeutics. Ultragenyx Pharmaceutical's average media sentiment score of 1.33 beat Mineralys Therapeutics' score of 1.06 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ultragenyx Pharmaceutical 7 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Mineralys Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger valuation & earnings, RARE or MLYS? Mineralys Therapeutics has lower revenue, but higher earnings than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Mineralys Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUltragenyx Pharmaceutical$560.23M5.85-$569.18M-$6.34-5.51Mineralys TherapeuticsN/AN/A-$177.81M-$3.64-3.82 Do analysts recommend RARE or MLYS? Ultragenyx Pharmaceutical presently has a consensus target price of $92.79, suggesting a potential upside of 165.71%. Mineralys Therapeutics has a consensus target price of $33.00, suggesting a potential upside of 137.07%. Given Ultragenyx Pharmaceutical's higher possible upside, analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Mineralys Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ultragenyx Pharmaceutical 0 Sell rating(s) 1 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.93Mineralys Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in RARE or MLYS? Ultragenyx Pharmaceutical received 819 more outperform votes than Mineralys Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Mineralys Therapeutics an outperform vote while only 77.52% of users gave Ultragenyx Pharmaceutical an outperform vote. CompanyUnderperformOutperformUltragenyx PharmaceuticalOutperform Votes83877.52% Underperform Votes24322.48% Mineralys TherapeuticsOutperform Votes19100.00% Underperform VotesNo Votes Do institutionals & insiders believe in RARE or MLYS? 97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. Comparatively, 84.5% of Mineralys Therapeutics shares are owned by institutional investors. 5.8% of Ultragenyx Pharmaceutical shares are owned by insiders. Comparatively, 33.2% of Mineralys Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Is RARE or MLYS more profitable? Mineralys Therapeutics has a net margin of 0.00% compared to Ultragenyx Pharmaceutical's net margin of -101.60%. Mineralys Therapeutics' return on equity of -67.97% beat Ultragenyx Pharmaceutical's return on equity.Company Net Margins Return on Equity Return on Assets Ultragenyx Pharmaceutical-101.60% -193.80% -38.15% Mineralys Therapeutics N/A -67.97%-62.40% Which has more volatility & risk, RARE or MLYS? Ultragenyx Pharmaceutical has a beta of 0.61, meaning that its stock price is 39% less volatile than the S&P 500. Comparatively, Mineralys Therapeutics has a beta of -0.39, meaning that its stock price is 139% less volatile than the S&P 500. SummaryUltragenyx Pharmaceutical beats Mineralys Therapeutics on 9 of the 17 factors compared between the two stocks. Remove Ads Get Mineralys Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MLYS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MLYS vs. The Competition Export to ExcelMetricMineralys TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$873.97M$6.35B$5.35B$7.58BDividend YieldN/A3.23%5.11%4.33%P/E Ratio-3.826.7721.7617.79Price / SalesN/A229.14376.0394.59Price / CashN/A65.6738.1534.64Price / Book3.635.886.443.99Net Income-$177.81M$141.32M$3.20B$247.24M7 Day Performance18.27%8.32%6.16%6.12%1 Month Performance-2.32%-12.93%-8.82%-7.11%1 Year Performance12.80%-12.47%9.66%-0.85% Mineralys Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MLYSMineralys Therapeutics2.5719 of 5 stars$13.92+3.9%$33.00+137.1%+7.0%$873.97MN/A-3.8228Short Interest ↑Gap DownRAREUltragenyx Pharmaceutical4.5535 of 5 stars$32.14-0.9%$92.79+188.7%-25.7%$3.02B$560.23M-5.071,310Positive NewsGap DownAKROAkero Therapeutics4.3006 of 5 stars$35.97-2.1%$76.29+112.1%+69.5%$2.86BN/A-9.5930Positive NewsGap UpHigh Trading VolumeMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730SWTXSpringWorks Therapeutics2.0398 of 5 stars$36.99-5.4%$73.20+97.9%-12.4%$2.77B$191.59M-10.63230Positive NewsGap UpHigh Trading VolumePTGXProtagonist Therapeutics3.813 of 5 stars$43.21-2.8%$62.56+44.8%+66.5%$2.65B$434.43M16.24120Positive NewsCPRXCatalyst Pharmaceuticals4.5519 of 5 stars$21.81-5.5%$32.29+48.0%+49.8%$2.65B$491.73M18.4880Positive NewsGap DownHigh Trading VolumeMRUSMerus2.8207 of 5 stars$37.39-1.9%$85.31+128.2%+1.4%$2.58B$36.13M-9.4737Positive NewsALVOAlvotech1.7031 of 5 stars$8.32-2.1%$18.00+116.3%-30.3%$2.51B$489.68M-4.501,026Analyst RevisionGap DownAPLSApellis Pharmaceuticals4.1457 of 5 stars$19.80-0.9%$45.59+130.2%-62.7%$2.49B$781.37M-9.75770Gap DownSRRKScholar Rock3.8873 of 5 stars$26.04-3.2%$42.67+63.9%+115.1%$2.47B$33.19M-11.08140Positive NewsGap Up Remove Ads Related Companies and Tools Related Companies RARE Competitors AKRO Competitors MOR Competitors SWTX Competitors PTGX Competitors CPRX Competitors MRUS Competitors ALVO Competitors APLS Competitors SRRK Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MLYS) was last updated on 4/15/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredElon’s Silver Play? Trump Clears the PathNothing is confirmed—yet. But Musk has disrupted every industry he's touched, and Trump's policies make the ti...Priority Gold | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mineralys Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mineralys Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MLYS Stock Free MLYS Stock Alerts